There's plenty of untapped potential left in genomics, but there are quite a few other omics investors need to know about heading into 2020.
Investors have lost faith in the biopharma, which is sitting at its lowest market cap in two years. But Wall Street may be overlooking a significant catalyst from a partnered asset.
A settlement in a closely watched Ohio case averted a federal trial and paves the way to a nationwide settlement -- if drug companies shorten their payment timelines.
The company is a one-trick pony, but should generate profits for the foreseeable future. Can the pipeline finally come through for investors?
The gene therapy stock is trading at its lowest level in over two years. It recently announced preliminary third-quarter 2019 operating results.
The company announced an unexpectedly favorable settlement in a lawsuit related to the opioid epidemic.
The small-cap company's shares have fallen 64% in the last year, but a promising drug portfolio might signal an opportunity for investors with a long-term mindset.
Most people are way too pessimistic relative to what's likely in store for American renewable energy.
A surge in wind power can blow coal down the rankings in the near future. These renewable energy stocks could benefit.
American Electric Power is one of the largest utility holding companies in the United States, but it's lagging behind its peers in renewable energy.
The company reported promising updates for two important pipeline programs.
The filings provide a glimpse of the company's struggles. Can cannabinoids pull the business out of the doldrums?
The year may be drawing to a close, but this biomanufacturing stock -- and any investor interested in it -- has plenty to look forward to.
An important regulatory milestone has been pushed back to late December, although investors will be awaiting voting results from a meeting in mid-November.
The United States and China reached a partial deal in the ongoing trade war.
A new slide deck shows reasons for optimism.
An analyst downgrade is only adding to the company's woes.
An analyst downgrade and a departing executive make for a bad day.
A big contract could keep fueling growth.
The genetic-testing stock can't seem to escape the trap of volatility.